Invivyd, Inc. Announces CMO Departure and Interim Appointment
Ticker: IVVD · Form: 8-K · Filed: Aug 27, 2024 · CIK: 1832038
| Field | Detail |
|---|---|
| Company | Invivyd, INC. (IVVD) |
| Form Type | 8-K |
| Filed Date | Aug 27, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, biotech, personnel
TL;DR
Invivyd's CMO is out, interim CMO in. Big changes for ADG20 development?
AI Summary
On August 27, 2024, Invivyd, Inc. filed an 8-K report detailing the resignation of Dr. David M. Apelian from his role as Chief Medical Officer, effective August 26, 2024. The company also announced the appointment of Dr. Erin Coller as interim Chief Medical Officer. This change comes as Invivyd continues its development of ADG20, a monoclonal antibody for the treatment and prevention of COVID-19.
Why It Matters
The departure of a Chief Medical Officer can signal shifts in a company's strategic direction or challenges in its drug development pipeline, potentially impacting investor confidence and future research outcomes.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially in a clinical-stage biotech company, can introduce uncertainty regarding the future direction and execution of its development programs.
Key Players & Entities
- Invivyd, Inc. (company) — Registrant
- Dr. David M. Apelian (person) — Resigning Chief Medical Officer
- Dr. Erin Coller (person) — Appointed interim Chief Medical Officer
- ADG20 (drug) — Product under development
- August 27, 2024 (date) — Filing date
- August 26, 2024 (date) — Effective date of CMO resignation
FAQ
What is the reason for Dr. David M. Apelian's departure as Chief Medical Officer?
The filing does not specify the reason for Dr. Apelian's resignation, only that it was effective August 26, 2024.
Who has been appointed as the interim Chief Medical Officer for Invivyd, Inc.?
Dr. Erin Coller has been appointed as the interim Chief Medical Officer.
What is the primary product Invivyd, Inc. is developing that may be affected by this change?
Invivyd, Inc. is developing ADG20, a monoclonal antibody for the treatment and prevention of COVID-19.
When was this 8-K filing submitted to the SEC?
The 8-K filing was submitted on August 27, 2024.
What was Invivyd, Inc.'s former company name?
Invivyd, Inc.'s former company name was Adagio Therapeutics, Inc.
Filing Stats: 487 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-08-27 08:05:02
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share IVVD The Nasdaq Stock Mar
Filing Documents
- d890200d8k.htm (8-K) — 24KB
- d890200dex991.htm (EX-99.1) — 45KB
- d890200dex992.htm (EX-99.2) — 20KB
- g890200ex99_2p10g1.jpg (GRAPHIC) — 451KB
- g890200ex99_2p11g1.jpg (GRAPHIC) — 168KB
- g890200ex99_2p12g1.jpg (GRAPHIC) — 259KB
- g890200ex99_2p13g1.jpg (GRAPHIC) — 141KB
- g890200ex99_2p14g1.jpg (GRAPHIC) — 218KB
- g890200ex99_2p15g1.jpg (GRAPHIC) — 135KB
- g890200ex99_2p16g1.jpg (GRAPHIC) — 295KB
- g890200ex99_2p17g1.jpg (GRAPHIC) — 73KB
- g890200ex99_2p1g1.jpg (GRAPHIC) — 432KB
- g890200ex99_2p2g1.jpg (GRAPHIC) — 650KB
- g890200ex99_2p3g1.jpg (GRAPHIC) — 397KB
- g890200ex99_2p4g1.jpg (GRAPHIC) — 296KB
- g890200ex99_2p5g1.jpg (GRAPHIC) — 79KB
- g890200ex99_2p6g1.jpg (GRAPHIC) — 213KB
- g890200ex99_2p7g1.jpg (GRAPHIC) — 154KB
- g890200ex99_2p8g1.jpg (GRAPHIC) — 212KB
- g890200ex99_2p9g1.jpg (GRAPHIC) — 290KB
- g890200g0827085405621.jpg (GRAPHIC) — 2KB
- 0001193125-24-207466.txt ( ) — 6386KB
- ivvd-20240827.xsd (EX-101.SCH) — 3KB
- ivvd-20240827_lab.xml (EX-101.LAB) — 18KB
- ivvd-20240827_pre.xml (EX-101.PRE) — 11KB
- d890200d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INVIVYD, INC. Date: August 27, 2024 By: /s/ Jill Andersen Jill Andersen Chief Legal Officer and Corporate Secretary